Discovery Laboratories Inc. (DSCOD) said it could be able to file a complete response with the U.S. Food and Drug Administration early in the third quarter on Surfaxin, its experimental preventative drug for respiratory distress syndrome in premature infants.

The drug developer, which had said in June the filing was on track for the first quarter, now says it has had multiple discussions with the agency regarding tests on the drug.

Like many drug developers, Discovery Labs has been unprofitable as it generates no revenue. It enacted a 1-for-15 reverse stock split last month in order to keep its Nasdaq listing and earlier this year sold stock and warrants, seeking proceeds for research and development.

Shares were down 1.9% at $3.63 in premarket activity.

-By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; matthew.jarzemsky@dowjones.com
Discovery Laboratories, Inc. (MM) (NASDAQ:DSCOD)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Discovery Laboratories, Inc. (MM) Charts.
Discovery Laboratories, Inc. (MM) (NASDAQ:DSCOD)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Discovery Laboratories, Inc. (MM) Charts.